Developer docs
API playgroundTry for free, no card

Search company profiles

Imagine Pharma

Full company profile

uuid0002tco

Namestring
Imagine Pharma
Legal namestring
Imagine Pharma LLC
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Imagine Pharma is a Pittsburgh, Pennsylvania-based biotechnology company founded in 2016 that operates as a drug discovery and development platform anchored by a proprietary polypeptide called IMG-1, discovered by Dr. Ngoc Thai in a tea plant. The company has organized its technology into three platforms: an oral drug delivery system branded as the PT System, a therapeutics pipeline, and a regenerative medicine program. In parallel with its pharmaceutical development activities, Imagine Pharma operates an Islet Isolation Center that performs both clinical and research isolations, serving diabetes researchers and transplant programs.

The company's pharmaceutical pipeline spans multiple therapeutic areas and routes of administration. The PT oral delivery platform underpins PT-1 (an oral erythropoietin formulation), PT-2 (oral octreotide for acromegaly and neuroendocrine tumors), and PT-3 (a GLP-1 agonist for metabolic disease). A separate topical program includes Top-1, Top-2, and Top-3 candidates, and the regenerative medicine arm is developing autologous insulin-producing cells (AIPCs). On the commercial side, the company sells a consumer peptide supplement branded Progenalen Pro Peptide, distributed through partner Designs for Health. Revenue mechanics appear to derive from a mix of consumer supplement sales, fee-for-service islet isolation procedures, and collaborative research with institutional and biotech partners including Cook MyoSite, LyGenesis, WVU Medicine, and the NIDDK-sponsored Integrated Islet Distribution Program (IIDP).

The company completed a $32.5 million Series A financing in October 2023 led by IP Investors LLC, bringing total disclosed funding to approximately $40 million. With a headcount of 1–10 employees, Imagine Pharma operates as a capital-efficient, platform-oriented biotech, prioritizing pipeline breadth and partnership-based commercialization over large-scale in-house development infrastructure.

Short descriptiontext

Imagine Pharma is a Pittsburgh-based biotech founded in 2016 that develops oral and topical peptide therapeutics using its proprietary IMG-1 polypeptide platform, operates an Islet Isolation Center for diabetes research, and sells a consumer peptide supplement through distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologic oral delivery, islet cell isolation, regenerative cell therapy, diabetes therapeutics, drug discovery platform
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biotechnology / Drug Discovery & Development
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model6 records
1Government/NIH Grants & Contracts
TypeProfessional Services
Description

Contract awarded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Integrated Islet Distribution Program (IIDP) effective August 1, 2022, providing human islets to over 100 investigators and research programs.

imaginepharma.com
2Clinical Islet Isolation Services
TypeProfessional Services
Description

Fee-for-service clinical human islet cell isolation procedures for hospital systems lacking in-house capabilities. Completed 40+ procedures over 14 months (31 in 2024, 9 in 2025) including 24 pediatric procedures. Performed at Cook MyoSite facility in Pittsburgh.

imaginepharma.com
3Research Islet Isolations & Related Services
TypeProfessional Services
Description

Research-grade human isolated islets, pancreatic tissue processing, pancreatic tissue and islet cell banking, and pancreatic living slices sold to leading academic diabetes centers (Vanderbilt, Stanford, U Florida, Mt. Sinai, U Pittsburgh, nPOD, etc.). 48 research isolations completed in 2024.

imaginepharma.com
4Licensing & Distribution Royalties
TypeLicensing Royalties
Description

Exclusive distribution and licensing agreement with Designs for Health for Progenalen Pro Peptide dietary supplement, generating licensing royalties and product revenue through healthcare professional channel (29,000 practitioners).

imaginepharma.com
5Consumer Supplement Sales (Progenalen)
TypeHardware Sales
Description

Direct-to-consumer sales of Progenalen Life+ supplement via progenalen.com storefront; pursuing strategic channel and distribution partnerships for consumer, corporate, and specialty markets.

imaginepharma.com
6Equity & Debt Securities Offerings
TypeTransaction Fee
Description

Exempt securities offering filed via SEC Form D as a Delaware LLC, with $300,000 total amount sold and $50,000 minimum investment.

sec.gov
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Custom quote-based pricing for islet services
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing determined per inquiry based on number of islets (IEQ), purity range, fixation method, frequency, and purpose. Customers must submit detailed inquiry form.

imaginepharma.com
2Progenalen Pro Peptide - price not disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Available as liquid drops and licaps, distributed exclusively through Designs for Health to healthcare professionals; consumer pricing not publicly disclosed.

imaginepharma.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 record
1Progenalen
Description

A division of Imagine Pharma dedicated to supporting health and wellness, producing science-backed dietary supplements (Progenalen Pro Peptide, Progenalen Professional for healthcare professionals, and Progenalen Life+ for consumers) formulated with the IMG-1 polypeptide.

imaginepharma.com
Core offering1 text field

Imagine Pharma is a biotechnology company developing first-in-class therapeutics and regenerative medicine built around its proprietary IMG-1 polypeptide. It commercializes clinical and research-grade human islet isolation services for hospital systems and academic research centers, develops oral biologic delivery and cell therapy programs (PT-1 EPO, PT-2 Octreotide, PT-3 GLP-1 Agonist, Topical wound healing, AIPCs for Type 1 diabetes), and sells the Progenalen dietary supplement line formulated with IMG-1.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 20+ million pancreatic islets isolated for clinical and research use since January 2024
+4 more records
Product and service5 records
1Clinical Human Islet Cell Isolation Services
CategoryBiotech services / cell isolation services
2Research Islet Supply & Pancreatic Tissue Services
CategoryBiotech services / research tissue supply
3NIDDK IIDP Human Islet Supply
CategoryGovernment / NIH-funded research supply
4Progenalen Pro Peptide
CategoryDietary supplement (professional / healthcare practitioner channel)
5Progenalen Life+ Consumer Supplement
CategoryDietary supplement (consumer)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagship Commercial Distribution Partner For Progenalen Pro PeptideTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-20
Description

Exclusive distribution and licensing agreement for Progenalen Pro Peptide dietary supplement. Gives Imagine Pharma access to Designs for Health's community of 29,000 health and wellness professionals nationwide. Progenalen Pro Peptide contains Imagine Pharma's IMG-1® polypeptide and is marketed as a professional-grade, once-daily supplement for health span and healthy aging.

Strategic tierCore Marketing/Communications PartnerTypeGTM or Marketing PartnerAnnounced on2025-02-20
Description

Strategic marketing and communications firm providing PR, IR, and strategic counsel. Co-CEO Santiago Pujadas is also co-chief executive officer at Zer0 to 5ive. Handles media relations and investor communications for Imagine Pharma.

Strategic tierMajor Healthcare System Customer-PartnerTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-05-28
Description

Contract to provide human clinical islet isolation services for patients undergoing total pancreatectomy and autologous islet cell transplant (TPAIT). WVU Health System is the state's largest health system (21 hospitals) and largest private employer. First transplantation procedure successfully completed at Cook MyoSite facility.

4Imagine Pharma Foundation
Strategic tierCore Mission-Aligned Nonprofit ArmTypeStrategic or Co-development PartnerAnnounced on2024-01-23
Description

Non-profit charitable organization formed to advance metabolic research with a focus on Veterans. John Paul Midolo appointed as first Executive Director. Foundation will collaborate with research institutions, pharma companies, healthcare providers, and other nonprofits on four key areas: metabolic/diabetes research, access to treatments for veterans, supporting other nonprofits, and education/awareness.

imaginepharma.com
Strategic tierCore Operational Partner For Clinical Islet IsolationTypeStrategic or Co-development PartnerAnnounced on2023-12-19
Description

Partnership formed to establish a state-of-the-art facility to conduct human islet isolations for hospital systems without in-house capabilities. Clinical isolations for total pancreatectomy and autologous islet transplantation are performed at Cook MyoSite's facility in Pittsburgh, PA. Enables expansion of clinical islet cell isolation capabilities.

Strategic tierFlagship Strategic Research Collaboration For Type 1 DiabetesTypeStrategic or Co-development PartnerAnnounced on2023-04-11
Description

Joint research collaboration to develop novel cell therapies for patients with Type 1 Diabetes. The research collaboration leverages Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis' allogeneic cell therapy platform, using the lymph node as a bioreactor to grow a functioning ectopic pancreas. Enables rapid advancement of a joint preclinical proof of concept program.

Strategic tierCore Federal Program Partner And RecognitionTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Imagine Pharma's Islet Center was selected as an approved Islet Isolation Center (IIC) under the NIDDK's Integrated Islet Distribution Program (IIDP), effective August 1, 2022. IIDP is the largest organized effort in the world to provide high-quality human islet preparations to the diabetes research community, supplying over 100 investigators. Imagine's Islet Center is one of only five IICs.

Strategic tierCore Facility PartnerTypeOEM/ Whitelabel/ Licensing Partner
Description

Imagine Pharma performs clinical islet isolations at the Cook MyoSite facility in Pittsburgh, PA. The facility is also featured in the Current Partners logo section of the Islet Programs page.

9Core (organ procurement organization partner)
Strategic tierOperational Partner For Islet ProcurementTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a Current Partner in the Islet Programs page; role related to organ/tissue procurement enabling islet isolation services.

imaginepharma.com
10Nevada Donor Network
Strategic tierOperational Partner For Islet ProcurementTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a Current Partner in the Islet Programs page; organ procurement organization enabling pancreatic tissue/islet supply.

imaginepharma.com
Strategic tierOperational Partner For Islet ProcurementTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a Current Partner in the Islet Programs page; organ procurement organization enabling pancreatic tissue/islet supply.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major pharma advancing VX-880, a stem cell-derived allogeneic islet cell therapy for Type 1 diabetes. Directly competes with Imagine Pharma's AIPC and T1D autologous transplant programs in pursuit of a functional T1D cure.

TypeBroad incumbent
Description

Global diabetes and obesity leader with Rybelsus (oral GLP-1), Ozempic/Wegovy and a deep diabetes pipeline. Dominant incumbent whose commercial reach and capital set the competitive bar for Imagine Pharma's PT-3 oral GLP-1 agonist and T1D programs.

TypeDirect peer
Description

Clinical-stage company developing an oral insulin capsule (ORMD-0801) and oral delivery platform for biologic drugs. Direct competitor to Imagine Pharma's PT Oral Delivery system and PT-3 oral GLP-1 agonist.

TypeEmerging player
Description

Well-funded emerging biotech pursuing next-generation oral and injectable GLP-1 and obesity therapies. Comparable emerging player challenging the same oral GLP-1 market segment as Imagine Pharma's PT-3 program.

5Sigilon Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing encapsulated cell therapies for Type 1 diabetes and other serious diseases. Directly comparable to Imagine Pharma's regenerative medicine platform for insulin-dependent diabetes.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cell therapies using the lymph node as a bioreactor, including for Type 1 diabetes. Active research collaboration partner with Imagine Pharma combining LyGenesis' platform with Imagine's T1D AIPCs; co-founder/CEO Michael Hufford sits on Imagine Pharma's advisory board.

TypeEmerging player
Description

Preclinical-stage cell therapy company developing stem cell-derived islet replacement for Type 1 diabetes. Comparable emerging player in the T1D cell therapy space alongside Imagine Pharma's AIPC program.

TypeDirect peer
Description

Clinical-stage biotech developing an oral (pill-based) biologic delivery platform for peptides and large molecules. Directly comparable to Imagine Pharma's PT Oral Delivery platform as both pursue oral alternatives to injectable biologics.

TypeBroad incumbent
Description

Major pharma leader in diabetes/obesity with Mounjaro/Zepbound and an emerging oral GLP-1 (orforglipron). Sets the competitive benchmark in oral GLP-1 that Imagine Pharma's PT-3 program must beat on differentiation, efficacy, or convenience.

TypeDirect peer
Description

Cell therapy company developing autologous cell therapies including for diabetes, with a focus on point-of-care cell processing and immune modulation. Comparable to Imagine Pharma in regenerative medicine and cell-based therapies for metabolic disease.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imagine Pharma

Biotechnology / Drug Discovery & Developmentimaginepharma.com

Imagine Pharma is a Pittsburgh-based biotech founded in 2016 that develops oral and topical peptide therapeutics using its proprietary IMG-1 polypeptide platform, operates an Islet Isolation Center for diabetes research, and sells a consumer peptide supplement through distribution partners.

What Imagine Pharma does

Imagine Pharma is a Pittsburgh, Pennsylvania-based biotechnology company founded in 2016 that operates as a drug discovery and development platform anchored by a proprietary polypeptide called IMG-1, discovered by Dr. Ngoc Thai in a tea plant. The company has organized its technology into three platforms: an oral drug delivery system branded as the PT System, a therapeutics pipeline, and a regenerative medicine program. In parallel with its pharmaceutical development activities, Imagine Pharma operates an Islet Isolation Center that performs both clinical and research isolations, serving diabetes researchers and transplant programs.

The company's pharmaceutical pipeline spans multiple therapeutic areas and routes of administration. The PT oral delivery platform underpins PT-1 (an oral erythropoietin formulation), PT-2 (oral octreotide for acromegaly and neuroendocrine tumors), and PT-3 (a GLP-1 agonist for metabolic disease). A separate topical program includes Top-1, Top-2, and Top-3 candidates, and the regenerative medicine arm is developing autologous insulin-producing cells (AIPCs). On the commercial side, the company sells a consumer peptide supplement branded Progenalen Pro Peptide, distributed through partner Designs for Health. Revenue mechanics appear to derive from a mix of consumer supplement sales, fee-for-service islet isolation procedures, and collaborative research with institutional and biotech partners including Cook MyoSite, LyGenesis, WVU Medicine, and the NIDDK-sponsored Integrated Islet Distribution Program (IIDP).

The company completed a $32.5 million Series A financing in October 2023 led by IP Investors LLC, bringing total disclosed funding to approximately $40 million. With a headcount of 1–10 employees, Imagine Pharma operates as a capital-efficient, platform-oriented biotech, prioritizing pipeline breadth and partnership-based commercialization over large-scale in-house development infrastructure.

Imagine Pharma firmographics

Firmographics
Name
Imagine Pharma
Legal name
Imagine Pharma LLC
Website
https://imaginepharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Imagine Pharma is a Pittsburgh-based biotech founded in 2016 that develops oral and topical peptide therapeutics using its proprietary IMG-1 polypeptide platform, operates an Islet Isolation Center for diabetes research, and sells a consumer peptide supplement through distribution partners.
Ownership category
akta.pro rank

Imagine Pharma industry classification

Industry
Product category
Biotechnology / Drug Discovery & Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Biologic oral delivery
  • Islet cell isolation
  • Regenerative cell therapy
  • Diabetes therapeutics
  • Drug discovery platform

Where Imagine Pharma is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Imagine Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Government/NIH Grants & Contracts: Contract awarded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Integrated Islet Distribution Program (IIDP) effective August 1, 2022, providing human islets to over 100 investigators and research programs.
  2. Clinical Islet Isolation Services: Fee-for-service clinical human islet cell isolation procedures for hospital systems lacking in-house capabilities. Completed 40+ procedures over 14 months (31 in 2024, 9 in 2025) including 24 pediatric procedures. Performed at Cook MyoSite facility in Pittsburgh.
  3. Research Islet Isolations & Related Services: Research-grade human isolated islets, pancreatic tissue processing, pancreatic tissue and islet cell banking, and pancreatic living slices sold to leading academic diabetes centers (Vanderbilt, Stanford, U Florida, Mt. Sinai, U Pittsburgh, nPOD, etc.). 48 research isolations completed in 2024.
  4. Licensing & Distribution Royalties: Exclusive distribution and licensing agreement with Designs for Health for Progenalen Pro Peptide dietary supplement, generating licensing royalties and product revenue through healthcare professional channel (29,000 practitioners).
  5. Consumer Supplement Sales (Progenalen): Direct-to-consumer sales of Progenalen Life+ supplement via progenalen.com storefront; pursuing strategic channel and distribution partnerships for consumer, corporate, and specialty markets.
  6. Equity & Debt Securities Offerings: Exempt securities offering filed via SEC Form D as a Delaware LLC, with $300,000 total amount sold and $50,000 minimum investment.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCustom quote-based pricing for islet services
OtherPay-as-you-goProgenalen Pro Peptide - price not disclosed

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Imagine Pharma product offering

Product offering

Core offering

Imagine Pharma is a biotechnology company developing first-in-class therapeutics and regenerative medicine built around its proprietary IMG-1 polypeptide. It commercializes clinical and research-grade human islet isolation services for hospital systems and academic research centers, develops oral biologic delivery and cell therapy programs (PT-1 EPO, PT-2 Octreotide, PT-3 GLP-1 Agonist, Topical wound healing, AIPCs for Type 1 diabetes), and sells the Progenalen dietary supplement line formulated with IMG-1.

Differentiator

Problem solved

Functional benefit

Brands

  • Progenalen: A division of Imagine Pharma dedicated to supporting health and wellness, producing science-backed dietary supplements (Progenalen Pro Peptide, Progenalen Professional for healthcare professionals, and Progenalen Life+ for consumers) formulated with the IMG-1 polypeptide.

Products and services

  • Clinical Human Islet Cell Isolation Services
  • Research Islet Supply & Pancreatic Tissue Services
  • NIDDK IIDP Human Islet Supply
  • Progenalen Pro Peptide
  • Progenalen Life+ Consumer Supplement

Quantifiable outcome

  • 20+ million pancreatic islets isolated for clinical and research use since January 2024
  • +4 more outcomes

Companies that use Imagine Pharma

Customer profile

Named customers12 records

Segments5 records

Ideal customer profiles5 records

Imagine Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Imagine Pharma partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship commercial distribution partner for progenalen pro peptide, core marketing/communications partner, major healthcare system customer-partner, core mission-aligned nonprofit arm, core operational partner for clinical islet isolation, flagship strategic research collaboration for type 1 diabetes, core federal program partner and recognition, core facility partner and operational partner for islet procurement.

  • Designs for Health, Inc.flagship commercial distribution partner for progenalen pro peptideChannel Partner/ Reseller/ Distributor · 20 February 2025Exclusive distribution and licensing agreement for Progenalen Pro Peptide dietary supplement. Gives Imagine Pharma access to Designs for Health's community of 29,000 health and wellness professionals nationwide. Progenalen Pro Peptide contains Imagine Pharma's IMG-1® polypeptide and is marketed as a professional-grade, once-daily supplement for health span and healthy aging.
  • Zer0 to 5ivecore marketing/communications partnerGTM or Marketing Partner · 20 February 2025Strategic marketing and communications firm providing PR, IR, and strategic counsel. Co-CEO Santiago Pujadas is also co-chief executive officer at Zer0 to 5ive. Handles media relations and investor communications for Imagine Pharma.
  • West Virginia University (WVU) Health System / WVU Medicinemajor healthcare system customer-partnerImplementation/ SI/ Consulting Partner · 28 May 2024Contract to provide human clinical islet isolation services for patients undergoing total pancreatectomy and autologous islet cell transplant (TPAIT). WVU Health System is the state's largest health system (21 hospitals) and largest private employer. First transplantation procedure successfully completed at Cook MyoSite facility.
  • Imagine Pharma Foundationcore mission-aligned nonprofit armStrategic or Co-development Partner · 23 January 2024Non-profit charitable organization formed to advance metabolic research with a focus on Veterans. John Paul Midolo appointed as first Executive Director. Foundation will collaborate with research institutions, pharma companies, healthcare providers, and other nonprofits on four key areas: metabolic/diabetes research, access to treatments for veterans, supporting other nonprofits, and education/awareness.
  • Cook MyoSitecore operational partner for clinical islet isolationStrategic or Co-development Partner · 19 December 2023Partnership formed to establish a state-of-the-art facility to conduct human islet isolations for hospital systems without in-house capabilities. Clinical isolations for total pancreatectomy and autologous islet transplantation are performed at Cook MyoSite's facility in Pittsburgh, PA. Enables expansion of clinical islet cell isolation capabilities.
  • LyGenesis, Inc.flagship strategic research collaboration for type 1 diabetesStrategic or Co-development Partner · 11 April 2023Joint research collaboration to develop novel cell therapies for patients with Type 1 Diabetes. The research collaboration leverages Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis' allogeneic cell therapy platform, using the lymph node as a bioreactor to grow a functioning ectopic pancreas. Enables rapid advancement of a joint preclinical proof of concept program.
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / Integrated Islet Distribution Program (IIDP)core federal program partner and recognitionStrategic or Co-development Partner · 1 August 2022Imagine Pharma's Islet Center was selected as an approved Islet Isolation Center (IIC) under the NIDDK's Integrated Islet Distribution Program (IIDP), effective August 1, 2022. IIDP is the largest organized effort in the world to provide high-quality human islet preparations to the diabetes research community, supplying over 100 investigators. Imagine's Islet Center is one of only five IICs.
  • Cook (Cook Group) / Cook MyoSite facilitycore facility partnerOEM/ Whitelabel/ Licensing PartnerImagine Pharma performs clinical islet isolations at the Cook MyoSite facility in Pittsburgh, PA. The facility is also featured in the Current Partners logo section of the Islet Programs page.
  • Core (organ procurement organization partner)operational partner for islet procurementChannel Partner/ Reseller/ DistributorListed as a Current Partner in the Islet Programs page; role related to organ/tissue procurement enabling islet isolation services.
  • Nevada Donor Networkoperational partner for islet procurementChannel Partner/ Reseller/ DistributorListed as a Current Partner in the Islet Programs page; organ procurement organization enabling pancreatic tissue/islet supply.
  • Indiana Donor Networkoperational partner for islet procurementChannel Partner/ Reseller/ DistributorListed as a Current Partner in the Islet Programs page; organ procurement organization enabling pancreatic tissue/islet supply.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Imagine Pharma competitors and assessment

Company assessment

Direct peers

  • Vertex Pharmaceuticals: Major pharma advancing VX-880, a stem cell-derived allogeneic islet cell therapy for Type 1 diabetes. Directly competes with Imagine Pharma's AIPC and T1D autologous transplant programs in pursuit of a functional T1D cure.
  • Oramed Pharmaceuticals: Clinical-stage company developing an oral insulin capsule (ORMD-0801) and oral delivery platform for biologic drugs. Direct competitor to Imagine Pharma's PT Oral Delivery system and PT-3 oral GLP-1 agonist.
  • Sigilon Therapeutics: Clinical-stage biotech developing encapsulated cell therapies for Type 1 diabetes and other serious diseases. Directly comparable to Imagine Pharma's regenerative medicine platform for insulin-dependent diabetes.
  • LyGenesis: Clinical-stage cell therapy company developing allogeneic cell therapies using the lymph node as a bioreactor, including for Type 1 diabetes. Active research collaboration partner with Imagine Pharma combining LyGenesis' platform with Imagine's T1D AIPCs; co-founder/CEO Michael Hufford sits on Imagine Pharma's advisory board.
  • Rani Therapeutics: Clinical-stage biotech developing an oral (pill-based) biologic delivery platform for peptides and large molecules. Directly comparable to Imagine Pharma's PT Oral Delivery platform as both pursue oral alternatives to injectable biologics.
  • Orgenesis: Cell therapy company developing autologous cell therapies including for diabetes, with a focus on point-of-care cell processing and immune modulation. Comparable to Imagine Pharma in regenerative medicine and cell-based therapies for metabolic disease.

Broad incumbents

  • Novo Nordisk: Global diabetes and obesity leader with Rybelsus (oral GLP-1), Ozempic/Wegovy and a deep diabetes pipeline. Dominant incumbent whose commercial reach and capital set the competitive bar for Imagine Pharma's PT-3 oral GLP-1 agonist and T1D programs.
  • Eli Lilly: Major pharma leader in diabetes/obesity with Mounjaro/Zepbound and an emerging oral GLP-1 (orforglipron). Sets the competitive benchmark in oral GLP-1 that Imagine Pharma's PT-3 program must beat on differentiation, efficacy, or convenience.

Emerging players

  • Metsera: Well-funded emerging biotech pursuing next-generation oral and injectable GLP-1 and obesity therapies. Comparable emerging player challenging the same oral GLP-1 market segment as Imagine Pharma's PT-3 program.
  • Seraxis: Preclinical-stage cell therapy company developing stem cell-derived islet replacement for Type 1 diabetes. Comparable emerging player in the T1D cell therapy space alongside Imagine Pharma's AIPC program.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Imagine Pharma social profiles

Digital presence

Imagine Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imagine Pharma leadership team

Management profile

Number of profiles

Profiles14 records

Imagine Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Imagine Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imagine Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imagine Pharma

What does Imagine Pharma do?

Imagine Pharma is a biotechnology company developing first-in-class therapeutics and regenerative medicine built around its proprietary IMG-1 polypeptide. It commercializes clinical and research-grade human islet isolation services for hospital systems and academic research centers, develops oral biologic delivery and cell therapy programs (PT-1 EPO, PT-2 Octreotide, PT-3 GLP-1 Agonist, Topical wound healing, AIPCs for Type 1 diabetes), and sells the Progenalen dietary supplement line formulated with IMG-1.

Is Imagine Pharma a public or private company?

Imagine Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Imagine Pharma founded?

Imagine Pharma was founded in 2016. It employs 11 to 50 people.

Where is Imagine Pharma based?

Imagine Pharma is headquartered in Pittsburgh, United States, in the North America region.

How does Imagine Pharma make money?

Six revenue lines are on record. Government/NIH Grants & Contracts are the primary driver. The others are clinical Islet Isolation Services, research Islet Isolations & Related Services, licensing & Distribution Royalties, consumer Supplement Sales (Progenalen) and equity & Debt Securities Offerings.

Who are Imagine Pharma's main competitors?

Direct peers on record are Vertex Pharmaceuticals, Oramed Pharmaceuticals, Sigilon Therapeutics, LyGenesis, Rani Therapeutics and Orgenesis. Broad incumbents are Novo Nordisk and Eli Lilly. Emerging players are Metsera and Seraxis.

Does Imagine Pharma have an API?

No public API is recorded for Imagine Pharma.

What industry is Imagine Pharma in?

Imagine Pharma's product category is Biotechnology / Drug Discovery & Development. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireImagine Pharma Selects Designs for Health as Exclusive Distributor to the Healthcare Professional Market for its New, Science-Backed Dietary Supplement for Wellness and Healthy AgingImagine Pharma announced a distribution and licensing agreement with Designs for Health to market Progenalen Pro Peptide, a dietary supplement using its IMG-1 polypeptide, to Designs for Health's 29,000 health and wellness professionals. The supplement is formulated to support energy, joint mobility, and cardiovascular health, and will be available as liquid drops and licaps.YahooImagine Pharma Selects Designs for Health as Exclusive Distributor to the Healthcare Professional Market for its New, Science-Backed Dietary Supplement for Wellness and Healthy AgingImagine Pharma announced a distribution and licensing agreement with Designs for Health to market Progenalen Pro Peptide, a dietary supplement using its IMG-1 polypeptide, to Designs for Health's 29,000 healthcare professionals. The supplement is formulated to support cell regeneration and healthy aging, available as liquid drops and licaps.PR NewswireWest Virginia University Health System Selects Imagine Pharma to Provide Human Islet Isolation Services for Autologous Clinical TransplantationImagine Pharma has been awarded a contract by West Virginia University Health System to provide human clinical islet isolation services for autologous transplantation procedures. The company successfully completed the first such procedure at its Cook MyoSite facility in Pittsburgh, Pennsylvania. This partnership aims to support WVU Medicine's program for treating chronic pancreatitis through total pancreatectomy and autologous islet cell transplant.Pulse 2.0Imagine Pharma: $32.5 Million Raised For Development Of Novel IMG-1 Polypeptide And Associated ProgramsImagine Pharma raised $32.5 million in a Series A round led by IP Investors LLC, bringing total funding to $40 million. The funds will advance its IMG-1 polypeptide programs, including pre-clinical studies and IND submissions for oral erythropoietin and GLP-1 agonists.PR NewswireImagine Pharma Secures $32.5M Series A for Continued Development of Its Novel IMG-1 Polypeptide and Associated ProgramsImagine Pharma raised a $32.5 million Series A round led by IP Investors LLC, with an initial tranche of $10 million, bringing total funding to $40 million. The funds will advance its regenerative medicine, oral delivery, and therapeutics programs, including pre-clinical studies and IND submissions for oral erythropoietin and GLP-1 agonists.Pharmaceutical TechnologyLyGenesis, Imagine Pharma for type 1 diabetes therapiesClinical-stage biotechnology firm LyGenesis has entered a joint research collaboration with Imagine Pharma to develop new cell therapies for type 1 diabetes. The partnership will leverage LyGenesis’ allogeneic cell therapy platform and Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells to rapidly advance a preclinical proof of concept program.SecSEC FORM DImagine Pharma LLC filed a Form D with the SEC for an exempt securities offering under Rule 506(b) with a first sale date of December 30, 2022. The offering involves equity and debt securities secured by promissory notes, with a total amount sold reported as $300,000 USD to one investor.PR NewswireImagine Pharma Awarded Contract from National Institute of Diabetes and Digestive and Kidney Diseases's Integrated Islet Distribution Program to Provide Human IsletsImagine Pharma, a Pittsburgh-based biotechnology company, has been selected by the Integrated Islet Distribution Program (IIDP) as one of only five approved Islet Isolation Centers to provide human islets for diabetes research, with the award effective August 1, 2022. The IIDP, funded by the National Institute of Diabetes and Digestive and Kidney Diseases, is the world's largest coordinated effort to supply high-quality human islet preparations and currently supports over 100 investigators. Imagine Pharma's Islet Center, led by Dr. Rita Bottino, will supply human islet cells to leading academic diabetes centers across the United States.PR NewswireImagine Pharma Unveils Industry-First Generation of Insulin-Producing T1D Islet Cell Population at the American Transplant CongressImagine Pharma announced the discovery of Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) at the American Transplant Congress in Boston on June 6, 2022, describing it as an industry breakthrough for potential T1D treatment via autologous cell transplantation. The research successfully generated T1D AIPCs from 8 different tissue preparations from patients aged 27 to 58 years with long-standing diabetes (15+ years), with sufficient quantities produced to support transplantation procedures. The company envisions this novel cell population holds tremendous potential for treating and potentially curing type 1 diabetes, which affects approximately 1.6 million people in the US and more than 20 million worldwide.